Publications

ESMO open

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

01-08-2025

Urologic oncology

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.

01-05-2025

European urology oncology

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.

28-04-2025

Cancer chemotherapy and pharmacology

Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.

25-02-2025

Bladder cancer (Amsterdam, Netherlands)

Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes.

01-12-2024

BJC reports

Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.

23-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

13-09-2024

BMC cancer

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

25-07-2024

European urology

Management of Lymph Node-positive Penile Cancer: A Systematic Review.

01-03-2024

British journal of cancer

Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.

01-02-2024

International journal of radiation oncology, biology, physics

Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study.

01-01-2024

Nature medicine

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

01-01-2024

Nature medicine

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

01-12-2023

The New England journal of medicine

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

09-11-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.

01-11-2023

Nature medicine

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

01-03-2023

Urologic oncology

Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

01-07-2022

Urologic oncology

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.

01-03-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

01-03-2022

BMJ open

Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCI.

18-05-2021

Nature medicine

Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.

01-03-2021

PloS one

Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy.

23-05-2020

Nature medicine

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.

01-05-2020

Current opinion in urology

Management of the penile squamous cell carcinoma patient after node positive radical inguinal lymph node dissection: current evidence and future prospects.

01-03-2020

Future oncology (London, England)

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.

01-01-2020

European urology

Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.

01-12-2019

Nature communications

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

20-11-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

01-07-2019

Cancers

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.

29-03-2019

International journal of cancer

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

15-03-2019

The Journal of urology

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

01-03-2019

Oncotarget

Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma.

06-04-2018

Nature

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

22-02-2018

European journal of cancer (Oxford, England : 1990)

Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.

01-12-2016

Urologic oncology

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

01-10-2016

BMC cancer

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.

01-12-2013